EGFR and glioblastoma: While adult glioblastoma resistance typically develops from EGFR amplification or MGMT promoter methylation, pediatric H3K27M-mutant tumors evade treatment by employing chromatin remodeling and disrupted developmental processes (e.g., PRC2 dysfunction) [138].